A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

被引：0
|
作者：
Nadeem, Omar
Mo, Clifton C.
Laubach, Jacob P.
Bianchi, Giada
Redd, Robert
Barth, Peter
Bayliss, Trevor J.
Sanchorawala, Vaishali
Shune, Leyla
Distaso, Alexandra
Dalton, Virginia
Sperling, Adam S.
Amweg, Laura
McKenney, Mary
Colson, Kathleen
Millard, Ella L.
Hou, Isabella
Savell, Alexandra
Masone, Kelly
Munshi, Nikhil C.
Ghobrial, Irene M.
Anderson, Kenneth
Richardson, Paul G.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141549
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Nadeem, Omar
    Redd, Robert A.
    Barth, Peter
    Mo, Clifton C.
    Laubach, Jacob P.
    Bianchi, Giada
    Bayliss, Trevor J.
    Sanchorawala, Vaishali
    Shune, Leyla
    Distaso, Alexandra
    Dalton, Virginia
    McKenney, Mary
    Patches, Sarah
    Hou, Isabella
    Issokson, Lindsay
    Barrell, Anna
    Masone, Kelly
    Sperling, Adam S.
    Munshi, Nikhil C.
    Ghobrial, Irene M.
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2021, 138
  • [2] A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Nadeem, Omar
    Redd, Robert A.
    Bayliss, Trevor J.
    Barth, Peter
    Laubach, Jacob
    Mo, Clifton C.
    Bianchi, Giada
    Masone, Kelly
    Griffin, Kyle
    Issokson, Lindsay
    Barrell, Anna
    Doherty, Randi
    Mailand, Deborah
    Distaso, Alexandra
    Patches, Sarah
    Goodrich, Kathryn
    Oneill, Kathleen
    Sanchorawala, Vaishali
    Shune, Leyla O.
    Richardson, Paul G.
    BLOOD, 2022, 140 : 10180 - 10181
  • [3] Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    Amrita Krishnan
    Prashant Kapoor
    Joycelynne M. Palmer
    Ni-Chun Tsai
    Shaji Kumar
    Sagar Lonial
    Myo Htut
    Chatchada Karanes
    Nitya Nathwani
    Michael Rosenzweig
    Firoozeh Sahebi
    George Somlo
    Lupe Duarte
    James F. Sanchez
    Daniel Auclair
    Stephen J. Forman
    Jesus G. Berdeja
    Leukemia, 2018, 32 : 1567 - 1574
  • [4] Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    Krishnan, Amrita
    Kapoor, Prashant
    Palmer, Joycelynne M.
    Tsai, Ni-Chun
    Kumar, Shaji
    Lonial, Sagar
    Htut, Myo
    Karanes, Chatchada
    Nathwani, Nitya
    Rosenzweig, Michael
    Sahebi, Firoozeh
    Somlo, George
    Duarte, Lupe
    Sanchez, James F.
    Auclair, Daniel
    Forman, Stephen J.
    Berdeja, Jesus G.
    LEUKEMIA, 2018, 32 (07) : 1567 - 1574
  • [5] A phase I/II study of Pomalidomide, Ixazomib, Clarithromycin and Dexamethasone (PICd) in patients with relapsed or refractory Multiple Myeloma (RRMM)
    Rosenberg, Aaron
    Munoz, Meilen
    Costello, Caitlin
    Brem, Elizabeth
    Reid, Erin
    Maverakis, Emanual
    Kaesberg, Paul
    Lee, Lisa
    Abedi, Mehrdad
    Tuscano, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S157 - S158
  • [6] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Dhakal, Binod
    D'Souza, Anita
    Hamadani, Mehdi
    Arce-Lara, Carlos
    Schroeder, Katrina
    Chhabra, Saurabh
    Shah, Nirav N.
    Gauger, Katelyn
    Keaton, Taylor
    Pasquini, Marcelo
    Hari, Parameswaran
    BLOOD CANCER JOURNAL, 2019, 9 (8)
  • [7] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Binod Dhakal
    Anita D’Souza
    Mehdi Hamadani
    Carlos Arce-Lara
    Katrina Schroeder
    Saurabh Chhabra
    Nirav N. Shah
    Katelyn Gauger
    Taylor Keaton
    Marcelo Pasquini
    Parameswaran Hari
    Blood Cancer Journal, 9
  • [8] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
    Sara Bringhen
    Roberto Mina
    Anna Maria Cafro
    Anna Marina Liberati
    Stefano Spada
    Angelo Belotti
    Gianluca Gaidano
    Francesca Patriarca
    Rossella Troia
    Renato Fanin
    Lorenzo De Paoli
    Giuseppe Rossi
    Alessandra Lombardo
    Paola Bertazzoni
    Antonio Palumbo
    Pieter Sonneveld
    Mario Boccadoro
    Leukemia, 2018, 32 : 1803 - 1807
  • [9] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
    Bringhen, Sara
    Mina, Roberto
    Cafro, Anna Maria
    Liberati, Anna Marina
    Spada, Stefano
    Belotti, Angelo
    Gaidano, Gianluca
    Patriarca, Francesca
    Troia, Rossella
    Fanin, Renato
    De Paoli, Lorenzo
    Rossi, Giuseppe
    Lombardo, Alessandra
    Bertazzoni, Paola
    Palumbo, Antonio
    Sonneveld, Pieter
    Boccadoro, Mario
    LEUKEMIA, 2018, 32 (08) : 1803 - 1807
  • [10] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/ Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Padilla, Michelle
    Shah, Nina
    Sirianni, Lindsey
    Liu, Lin
    Cheng, Yuwei
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah
    Mulroney, Carolyn
    Ball, Edward D.
    Costello, Caitlin
    BLOOD, 2022, 140 : 4436 - 4437
12345